SBIR Phase I: Real-Time Allergen Detection Technology for Dietary Proteins Transferred to Human Milk

SBIR 第一阶段：转移到母乳中的膳食蛋白的实时过敏原检测技术

• 批准号: 2321861
• 负责人: Trillitye Paullin
• 金额: $ 27.49万
• 依托单位: FREE TO FEED, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2321861&HistoricalAwards=false
• 关键词: SBIR; Phase; Real; Time; Allergen

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to provide the first test to determine the allergen content of human milk accurately, quickly, and cost-effectively. As much as 25% of infants have reported allergic responses to dietary proteins found in human milk which often results in breast/body feeding termination. Breast/body feeding is incredibly beneficial to health and continuation of nursing is a human health issue. Studies indicate that human milk is superior to hypoallergenic formula, providing natural antibodies to fight illness, lowering the risk of sudden infant death syndrome, and reducing the probability of developing disorders such as diabetes and leukemia. There is currently no at-home, real-time test for milk allergens on the market.This Small Business Innovation Research (SBIR) Phase I project seeks to develop a real-time at-home allergen detection test. This project lays the groundwork for providing the first mechanism to research early and often allergen introduction through human milk when the immune system has been shown to be susceptible to allergy reduction strategies. The company’s patent-pending technology has the potential to provide a tool to identify allergens quickly and cost-effectively, allowing parents to monitor the presence of likely allergen triggers. The test is performed by the user in a real-time, in an at-home setting, which is a significant advantage over existing tests that require samples to be sent to a laboratory for labor and resource-intensive assays. The lateral flow technology provides a rapid and easy-to-read result, allowing the user to quickly determine whether the milk contains specific non-human protein fragments which are also known to elicit allergic responses in some patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛的影响/商业潜力是提供第一个测试，以准确，快速和经济有效地确定人牛奶的过敏原含量。多达25％的婴儿报告了对人乳中发现的饮食蛋白的过敏反应，这通常会导致乳房/身体喂养终止。乳房/身体喂养对健康非常有益，护士的延续是人类健康问题。研究表明，人类牛奶优于低过敏性配方，提供了与疾病作斗争的天然抗体，降低了婴儿猝死综合征的风险，并降低了糖尿病和白血病等疾病的可能性。目前，市场上尚无牛奶过敏原的实时测试。这项小型企业创新研究（SBIR）I阶段项目旨在开发实时的在家过敏原检测测试。该项目为在免疫系统被证明对减少过敏原策略敏感时提供了早期研究和通常通过人牛奶进行过敏原介绍的第一种机制。该公司的申请专利技术有可能提供一种工具来快速，成本效益，使父母可以监视可能的过敏原触发器。该测试是由用户实时在室内环境中实时执行的，这与现有测试相比，这是一个重要的优势，该测试需要将样品发送到实验室进行实验室和资源密集型测定法。横向流动技术提供了快速易于阅读的结果，使用户能够快速确定牛奶是否包含特定的非人类蛋白质片段，这些蛋白质片段是否也已知在某些患者中会引起过敏反应。该奖项反映了NSF的法定任务，并被认为是通过使用该基金会的知识分子和更广泛的影响来评估的支持，并被认为是值得的。